EUVIMEDEUVIMED entdecken
Open Access

A genome-wide genetic screen reveals the P2Y2-integrin axis as a stabilizer of EGFR mutants in non–small cell lung cancer (NSCLC)

Yafei Du iD, Wenjing Wang iD, Hui Chin Goh, Thamil Selvan Vaiyapuri iD, Anandhkumar Raju iD, Yu-Chun Hsiao, Cheng Chun Wang iD, Vanisha Agrawal iD, Noorul Farzana Mohideen, Norhidayah Binte Mohd Mazian iD, Feride Karatekin iD, Wendy Kehan Wang und 11 weitere

Science Advances · 23.01.2026 · 12 (4)

DOI: 10.1126/sciadv.adv3980 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Science Advances, erschienen am 23.01.2026. Verfasst von Yafei Du und 22 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Molecular and Cell Biology (IMCB), Agency for Science, Technology and Research (A∗STAR), 61 Biopolis Drive, Proteos, Singapore 138673, S…. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Receptors, Purinergic P2Y2, Lung Neoplasms, Mutation. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 102 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: A*STAR Career Development Award/Fund, National Research Foundation (NRF), Competitive Research Programme, National Medical Research Council (NMRC), Open Fund Individual Research Grant.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Activating mutations in the epidermal growth factor receptor ( EGFR ) gene drive non–small cell lung cancer (NSCLC). Oncogenic EGFR mutants are ligand-independent and more stable, but the underlying mechanism remains unclear. We hypothesized that EGFR mutants selectively leverage cellular stabilizers to evade degradation. Genome-wide RNA interference screens identified genes (encoding for stabilizers) responsible for mutant EGFR stability, with P2Y2 receptor (P2Y2) emerging as a bona fide stabilizer. Mechanistically, high extracellular adenosine triphosphate (ATP) levels transactivate EGFR mutants via P2Y2 activation, previously shown to signal through Src kinase–dependent EGFR phosphorylation. Our study reveals that ATP-driven P2Y2 activation stabilizes EGFR mutants by forming a P2Y2-integrin β1-EGFR complex enriched in endosomes. Targeting this axis destabilizes EGFR mutants and offers a strategy against drug resistance. Elevated P2Y2 and integrin β1 expression in patients with NSCLC implies clinical relevance. Our results provide previously unidentified insight that EGFR mutants enhance extracellular ATP levels to activate P2Y2-integrin for enhanced stability of EGFR mutants to drive the oncogenic program.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungReceptors, Purinergic P2Y2Lung NeoplasmsMutationIntegrin beta1HumansErbB ReceptorsAdenosine TriphosphateCell Line, TumorSignal TransductionRNA InterferencePhosphorylationGene Expression Regulation, NeoplasticGenetic Testing

Substanzen

ErbB ReceptorsReceptors, Purinergic P2Y2Integrin beta1EGFR protein, humanAdenosine TriphosphateP2RY2 protein, human

Autor:innen und Institutionen

  • Institute of Molecular and Cell Biology (IMCB), Agency for Science, Technology and Research (A∗STAR), 61 Biopolis Drive, Proteos, Singapore 138673, Singapore.
  • Department of Chemistry, National University of Singapore, Singapore, Singapore.
  • Center for Molecular Medicine, Research Center for Cancer Biology, and Graduate Institute of Biomedical Sciences, China Medical University, Taichung, Taiwan.
  • National Cancer Centre Singapore, 11 Hospital Crescent, Singapore 169610, Singapore.
  • School of Medicine, China Medical University, Taichung, Taiwan.
  • Department of Pathology, China Medical University Hospital, Taichung, Taiwan.

ORCID-Profile: Yafei Du, Wenjing Wang, Thamil Selvan Vaiyapuri, Anandhkumar Raju, Cheng Chun Wang, Vanisha Agrawal, Norhidayah Binte Mohd Mazian, Feride Karatekin, Manikandan Lakshmanan, Xavier Le Guezennec, Frederic Bard, Vinay Tergaonkar, Mien-Chie Hung, Xiaogang Liu, Wanjin Hong, Gandhi T K Boopathy

Förderung

  • A*STAR Career Development Award/Fund
  • National Research Foundation (NRF), Competitive Research Programme
  • National Medical Research Council (NMRC), Open Fund Individual Research Grant
  • IMCB Discovery Catalyst Grant 2025
  • ASTAR Biomedical Research Council (BMRC) Central Research Fund

Zitieren

APA

Du, Y., Wang, W., Goh, H. C., Vaiyapuri, T. S., Raju, A., Hsiao, Y. C., Wang, C. C., Agrawal, V., Mohideen, N. F., Mohd Mazian, N. B., Karatekin, F., Wang, W. K., Lakshmanan, M., Gupta, K., Chang, H., Le Guezennec, X., Bard, F., Tan, D. S. W., Tergaonkar, V., …, & Boopathy, G. T. K. (2026). A genome-wide genetic screen reveals the P2Y2-integrin axis as a stabilizer of EGFR mutants in non–small cell lung cancer (NSCLC). Science Advances, 12(4). https://doi.org/10.1126/sciadv.adv3980

Vancouver

Du Y, Wang W, Goh HC, Vaiyapuri TS, Raju A, Hsiao YC, et al. A genome-wide genetic screen reveals the P2Y2-integrin axis as a stabilizer of EGFR mutants in non–small cell lung cancer (NSCLC). Science Advances. 2026;12(4). doi:10.1126/sciadv.adv3980

BibTeX
@article{Du2026,
  author = {Du, Yafei and Wang, Wenjing and Goh, Hui Chin and Vaiyapuri, Thamil Selvan and Raju, Anandhkumar and Hsiao, Yu-Chun and Wang, Cheng Chun and Agrawal, Vanisha and Mohideen, Noorul Farzana and Mohd Mazian, Norhidayah Binte and Karatekin, Feride and Wang, Wendy Kehan and Lakshmanan, Manikandan and Gupta, Komal and Chang, Han and Le Guezennec, Xavier and Bard, Frederic and Tan, Daniel S W and Tergaonkar, Vinay and Hung, Mien-Chie and Liu, Xiaogang and Hong, Wanjin and Boopathy, Gandhi T K},
  title = {A genome-wide genetic screen reveals the P2Y2-integrin axis as a stabilizer of EGFR mutants in non–small cell lung cancer (NSCLC)},
  journal = {Science Advances},
  year = {2026},
  volume = {12},
  number = {4},
  doi = {10.1126/sciadv.adv3980}
}
Kostenlos starten →